Patients with active juvenile idiopathic arthritis–associated uveitis (n = 21) were treated with abatacept (ABA) when disease was refractory to topical corticosteroids and systemic immunosuppression. Comparison of systemic and topical treatment before and after ABA. Tapering of systemic corticosteroids and/or immunosuppressives was defined according to Saurenmann, et al24.
| Pt. | Treatment Prior to ABA | Baseline Treatment | Tapering of Systemic Corticosteroids and/or Immunosuppressives after ABA | Steroid Eyedrops Before/after ABA (no. times daily; +: periocular corticosteroid application) |
|---|---|---|---|---|
| 1 | PSL, MTX, ETA | MTX, ETA | No | 0/1 |
| 2 | PSL, MTX, CSA, IFX, ADA, IFN | PSL, MTX, CSA, ADA | Moderate | 2/5 (+) |
| 3 | PSL, MTX, ARA, ADA | PSL, MTX, ARA, ADA | No | 3/5 |
| 4 | PSL, MTX, CSA, ARA, ETA, ADA, RTX | MTX, CSA, ARA | No (rescue: PSL, RTX) | 7/12 (+) |
| 5 | PSL, MTX, AZA, ADA | PSL, AZA, ADA | No | 12/3 (+) |
| 6 | PSL, MTX, ADA | PSL, MTX, ADA | Moderate (rescue: IFX) | 4/3 |
| 7 | PSL, MTX, ADA | MTX, ADA | No (rescue: PSL) | 4/0 (+) |
| 8 | PSL, MTX, ADA | MTX, ADA | No | 0/3 |
| 9 | PSL, MTX, AZA, ARA, MMF, ETA, ADA | PSL, MTX, ADA | No | 5/3 |
| 10 | PSL, MTX, CSA, ADA | PSL, MTX | No | 4/0 |
| 11 | PSL, MTX, CSA, ADA | PSL, MTX, CSA | Good | 4/0 |
| 12 | PSL, MTX, AZA, CSA, ETA, IFX, ADA | PSL, MTX, CSA | No | 4/0 |
| 13 | PSL, MTX, CSA, IFX | PSL, MTX, CSA | No | 4/4 |
| 14 | PSL, MTX, CSA, IFX, ADA | PSL, MTX, CSA | No | 4/0 |
| 15 | PSL, MTX, ETA, IFX, ADA, GOL | MTX, GOL | No | 3/0 |
| 16 | PSL, MTX, IFX, ADA | MTX | No | 2/3 |
| 17 | PSL, MTX, MMF, IFX, ADA | MTX | No | 4/8 |
| 18 | PSL, MTX, CSA, IFX | CSA, IFX | No (rescue: ADA) | 5/2 |
| 19 | PSL, MTX, IFX, ADA | PSL, MTX, IFX | No | 1/3 |
| 20 | PSL, MTX, ETA, IFX | PSL, MTX | No | 2/1 |
| 21 | PSL, MTX, ETA, IFX, ADA | PSL, MTX, IFX | No | 4/0 |
Dosages were within the generally used ranges, e.g., for methotrexate (MTX) 15 mg/m2 weekly, azathioprine (AZA) 2 mg/kg body weight daily, cyclosporine (CSA) 3 mg/kg body weight daily, mycofenolate mofetil (MMF) 500–2000 mg daily, arava (ARA) 10–20 mg daily, etanercept (ETA) 0.8 mg/kg body weight weekly, infliximab (IFX) 5–6 mg/kg body weight bimonthly, adalimumab (ADA) 24 mg/m2 biweekly, rituximab (RTX) cycle 375 mg/m2, golimumab (GOL) 30 mg/m2 monthly, interferon-α2 (IFN) 1.5–3 Mio IU weekly. PSL: prednisolone.